An Indian manufacturer's perspective for harmonization of guidelines for similar biotherapeutic products
- PMID: 21816621
- DOI: 10.1016/j.biologicals.2011.06.022
An Indian manufacturer's perspective for harmonization of guidelines for similar biotherapeutic products
Abstract
This review focuses on the scenario of Indian manufacturers, biotherapeutics approvals in India and important aspects which need to be precisely analyzed and resolved from the Indian perspective to facilitate implementation of global guidelines for the manufacture of these products, to best serve the public health needs of the developing countries.
Copyright © 2011. Published by Elsevier Ltd.
Similar articles
-
China's perspective on similar biotherapeutic products.Biologicals. 2011 Sep;39(5):312-6. doi: 10.1016/j.biologicals.2011.06.020. Epub 2011 Sep 15. Biologicals. 2011. PMID: 21924622 Review.
-
Evaluation of similar biotherapeutic products: scientific and regulatory challenges.Biologicals. 2011 Sep;39(5):249. doi: 10.1016/j.biologicals.2011.09.004. Epub 2011 Sep 16. Biologicals. 2011. PMID: 21925898 No abstract available.
-
Current development in regulation of similar biotherapeutic products in Brazil.Biologicals. 2011 Sep;39(5):308-11. doi: 10.1016/j.biologicals.2011.06.021. Epub 2011 Aug 24. Biologicals. 2011. PMID: 21868247 Review.
-
Evaluation of similar biotherapeutic products (SBPs): scientific principles and their implementation.Biologicals. 2011 Sep;39(5):256-61. doi: 10.1016/j.biologicals.2011.08.008. Epub 2011 Sep 9. Biologicals. 2011. PMID: 21907589 Review.
-
Biosimilars and non-innovator biotherapeutics in India: an overview of the current situation.Biologicals. 2011 Sep;39(5):321-4. doi: 10.1016/j.biologicals.2011.06.018. Epub 2011 Jul 23. Biologicals. 2011. PMID: 21784652 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical